A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
Year: 2017
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dwight Hall Owen, Paul A. Bunn, Bruce E. Johnson, David J. Kwiatkowski, Mark G. Kris, Ignacio Ivan Wistuba, Mayank Gandhi, See Phan, David S. Shames, Katja Schulze, Wei Yu, Dara Aisner, Jamie E. Chaft, Edward B. Garon, Jay M Lee, John D. Minna, Valerie W. Rusch, Karen L. Reckamp, Antoinette J. Wozniak, David P. Carbone, LCMC3 Investigators
Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, University of Colorado Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Genentech, University of California, Los Angeles, The University of Texas Southwestern Medical Center, City Of Hope National Medical Center, The Barbara Ann Karmanos Cancer Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2739859697